PapersFlow Research Brief
Ocular Disorders and Treatments
Research Guide
What is Ocular Disorders and Treatments?
Ocular Disorders and Treatments is a research cluster encompassing genetic and clinical studies on eye malformations such as microphthalmia and anophthalmia, associated syndromes like Fraser syndrome, mutations in genes including SOX2 and BCOR, surgical interventions with orbital implants, and epidermal adhesion in ocular development.
The field includes 22,596 papers focused on genetic mutations and clinical management of ocular developmental disorders. Studies highlight defects in genes like those at the microphthalmia locus and SOX2 in conditions such as microphthalmia and anophthalmia. Research also covers gene therapy applications for inherited blindness and limbal autograft transplantation for ocular surface disorders.
Topic Hierarchy
Research Sub-Topics
SOX2 Mutations in Microphthalmia
Genetic studies identify SOX2 heterozygous mutations causing bilateral anophthalmia and microphthalmia syndromes. Functional assays reveal transcriptional dysregulation in ocular development pathways.
BCOR Mutations in Ocular Disorders
Sequencing analyses link BCOR hemizygous mutations to complex microphthalmia and anterior segment dysgenesis. Expression studies in model organisms probe BCOR's role in eye morphogenesis.
Fraser Syndrome Ocular Manifestations
Clinical-genetic research characterizes cryptophthalmos and lacrimo-auriculo-dento-digital defects in Fraser syndrome. Mutation screening of FRAS1 and FREM2 genes correlates genotypes with phenotypes.
Orbital Implants in Anophthalmia
Surgical outcome research evaluates hydroxyapatite and porous polyethylene implants for volume replacement in congenital anophthalmia. Long-term studies assess integration, extrusion rates, and cosmesis.
Genetic Regulation of Ocular Development
Developmental genetics investigates gene networks controlling lens placode induction and optic vesicle formation. Knockout models dissect hedgehog and BMP signaling in eye field specification.
Why It Matters
Gene therapy has restored vision in canine models of childhood blindness, as shown by Acland et al. (2001) in 'Gene therapy restores vision in a canine model of childhood blindness,' demonstrating feasibility for human Leber congenital amaurosis treatments. Phase 1 trials of RPE65 gene therapy for Leber's congenital amaurosis revealed age-dependent efficacy, with Maguire et al. (2009) reporting improved vision in young patients in 'Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.' Limbal autograft transplantation treats ocular surface disorders effectively, per Kenyon and Tseng (1989) in 'Limbal Autograft Transplantation for Ocular Surface Disorders.' These advances impact clinical practice in ophthalmology, enabling targeted therapies for genetic eye malformations.
Reading Guide
Where to Start
'Gene therapy restores vision in a canine model of childhood blindness' by Acland et al. (2001), as it provides a clear example of successful gene therapy application in an animal model of human ocular disorder, bridging genetics and treatment.
Key Papers Explained
Hodgkinson et al. (1993) in 'Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein' establishes genetic basis for microphthalmia, which connects to clinical gene therapy advances in Acland et al. (2001) 'Gene therapy restores vision in a canine model of childhood blindness' and Maguire et al. (2009) 'Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.' Kenyon and Tseng (1989) 'Limbal Autograft Transplantation for Ocular Surface Disorders' complements by addressing surgical treatments for surface disorders. Den Hollander et al. (2008) 'Leber congenital amaurosis: Genes, proteins and disease mechanisms' synthesizes mechanisms underlying these therapies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes genetic mutations in SOX2, BCOR, and syndromes like Fraser syndrome, with focus on orbital implants for eye malformations and epidermal adhesion roles, as no recent preprints or news indicate shifts from established genetic and clinical studies.
Papers at a Glance
Frequently Asked Questions
What genetic defects are linked to microphthalmia?
Mutations at the mouse microphthalmia locus associate with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein, as reported by Hodgkinson et al. (1993) in 'Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein.' These mutations contribute to ocular malformations including microphthalmia and anophthalmia.
How does gene therapy treat Leber congenital amaurosis?
Gene therapy targeting RPE65 restores vision in Leber congenital amaurosis, with age-dependent effects observed in phase 1 trials by Maguire et al. (2009) in 'Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.' It also succeeded in canine models of childhood blindness, per Acland et al. (2001) in 'Gene therapy restores vision in a canine model of childhood blindness.'
What is limbal autograft transplantation used for?
Limbal autograft transplantation addresses ocular surface disorders by transplanting limbal tissue, as detailed by Kenyon and Tseng (1989) in 'Limbal Autograft Transplantation for Ocular Surface Disorders.' This surgical method restores corneal epithelium in conditions like chemical burns or Stevens-Johnson syndrome.
What genes are implicated in Leber congenital amaurosis?
Leber congenital amaurosis involves mutations in multiple genes and their proteins, with disease mechanisms outlined by den Hollander et al. (2008) in 'Leber congenital amaurosis: Genes, proteins and disease mechanisms.' RPE65 is a key target for gene therapy interventions.
What role do genetic mutations play in Fraser syndrome?
Fraser syndrome associates with genetic mutations affecting ocular development, including those in SOX2 and BCOR genes, within studies on microphthalmia and anophthalmia. These mutations disrupt epidermal adhesion critical for eye formation.
Open Research Questions
- ? How do SOX2 and BCOR mutations specifically disrupt ocular development pathways in Fraser syndrome?
- ? What are the long-term outcomes of orbital implants in managing anophthalmia and microphthalmia?
- ? Can gene therapy approaches for RPE65 mutations be extended to other genes in Leber congenital amaurosis?
- ? What mechanisms link epidermal adhesion defects to eye malformations in genetic syndromes?
- ? How do basic-helix-loop-helix-zipper protein defects at the microphthalmia locus influence human ocular disorders?
Recent Trends
The field maintains 22,596 papers with no specified 5-year growth rate, centered on genetic studies of microphthalmia, anophthalmia, SOX2, and BCOR mutations, alongside surgical uses of orbital implants, without new preprints or news in the last 12 months.
Research Ocular Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ocular Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers